Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.70023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Yuki Ujihira und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Solute Carrier Organic Anion Transporter Family Member 1B3, Organic Anion Transporters, Sodium-Independent, Models, Biological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endogenous biomarkers for drug transporters are an emerging tool for the assessment of transporter‐mediated drug–drug interactions (DDI). Glycochenodeoxycholic acid 3‐O‐sulfate (GCDCA‐S) has been proposed as a Tier 2 biomarker of hepatic OATP1B3 and renal OAT3 transporters by the International Transporter Consortium. However, there are currently no mechanistic models developed for this biomarker. This study aimed to characterize the synthesis and elimination of this biomarker through population pharmacokinetic (POP‐PK) modeling of GCDCA‐S plasma and urine data in the presence and absence of OATP1B inhibitor rifampicin and OAT3 inhibitor probenecid. Simultaneous fitting of rifampicin and probenecid interaction data incorporated the inhibitory effect of rifampicin on GCDCA‐S hepatic clearance (CL h ) and probenecid inhibitory effect on both renal (CL R ) and hepatic (CL h ) clearance parameters, assuming no effect on the synthesis of GCDCA‐S. The POP‐PK model successfully described the observed data for GCDCA‐S, with reasonable standard errors (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
- Laboratory for Safety Assessment and ADME, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, Shizuoka, Japan.
- Pharmaceutical Sciences, Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Welwyn, UK.
ORCID-Profile: Yuki Ujihira, Viktor Georgiev, Kayode Ogungbenro, Aleksandra Galetin
Zitieren
APA
Ujihira, Y., Georgiev, V., Ogungbenro, K., & Galetin, A. (2025). Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70023
Vancouver
Ujihira Y, Georgiev V, Ogungbenro K, Galetin A. Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70023
BibTeX
@article{Ujihira2025,
author = {Ujihira, Yuki and Georgiev, Viktor and Ogungbenro, Kayode and Galetin, Aleksandra},
title = {Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.70023}
}
EUVIMED